Last updated: February 25, 2026
What Is NDC 69315-0323?
NDC 69315-0323 is associated with Evolocumab, marketed as Repatha. It is a monoclonal antibody used to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hyperlipidemia or cardiovascular risk. Approved by the FDA in 2015, it targets PCSK9 (proprotein convertase subtilisin/kexin type 9).
Current Market Landscape
Indications and Population
- FDA approval: 2015 for hyperlipidemia and familial hypercholesterolemia.
- Indications: Reduce LDL-C levels, adjunct therapy with diet and maximally tolerated statins.
- Patient population: Estimated at 10-15 million in the U.S. with indications for PCSK9 inhibitors, including familial hypercholesterolemia (~1 million) and high-risk atherosclerotic cardiovascular disease (ASCVD).
Competitors
- Alirocumab (Praluent): Also PCSK9 inhibitor, FDA approved 2015.
- Inclisiran (Leqvio): mRNA-based, approved 2020, administered biannually.
- Bempedoic acid (Nexletol): Approved 2019, oral therapy.
- Statins: First-line, large market share within lipid-lowering agents.
Market Trends
- Revenue: Repatha generated approximately $1.45 billion in global sales in 2022 (IQVIA).
- Market penetration: Partial, hindered by high cost, injection route, and patient compliance issues.
- Growth drivers: Expanding indications for cardiovascular risk reduction and increased insurer acceptance.
Pricing and Reimbursement Landscape
- List price: Approximately $14,100 annually per patient (per Gallagher et al., 2022).
- Average net price: Estimated at 40-50% of list price after rebates and discounts.
- Coverage: Varies by insurer; prior authorization required.
Price Projections
Short-Term (Next 1-2 Years)
- Expected discounts: Progressive insurer-driven rebates could reduce the net price by 10-15% annually.
- List price stability: No major reductions currently forecasted, but payers may negotiate better terms.
- Market expansion: Increased prescribing in high-risk populations may sustain revenue.
Long-Term (3-5 Years)
- Market competition: Introduction of biosimilars is unlikely soon due to patent exclusivity.
- Pricing pressure: Introduction of lower-cost alternatives like inclisiran and bempedoic acid could limit further price increases.
- Potential price decline: Net prices could decline 10-20% if biosimilar or value-based pricing models are adopted broadly.
Sensitivity Analysis: Cost-Effectiveness Impact
If the price drops by 20% over five years, the annual revenue could decrease proportionally unless volume growth offsets loss of per-unit revenue.
| Scenario |
Price Change |
Revenue Impact |
Comments |
| Base case |
0% |
Stable |
Current trends, no major changes |
| Moderate discounting |
-10% |
10% revenue decline |
Rebate increases, price stabilizes |
| Aggressive discounting |
-20% |
20% revenue decline |
Entry of biosimilars, cost pressures |
Regulatory and Policy Factors
- Price regulation: US Senate and House bills propose value-based pricing for high-cost drugs; potential to pressure prices downward.
- FDA policies: Push for biosimilar development may impact future pricing and market share.
- Insurer negotiations: Value-based contracts may influence net prices and utilization rates for Repatha.
Geographic Market Considerations
- US: Dominates revenue; high drug price elasticity driven by insurance coverage.
- Europe: More price controls; net prices generally lower.
- Emerging markets: Limited adoption due to affordability and infrastructure.
Strategic Implications
- Manufacturers: Focus on expanding indications, improving patient adherence, and pursuing biosimilar development.
- Investors: Monitor regulatory shifts and payer negotiations that could affect revenue.
- Payers: Emphasize value-based pricing to control costs, especially in expanding high-risk populations.
Key Takeaways
- NDC 69315-0323 (Repatha) has a mature market, with revenues around $1.45 billion globally.
- Price projections suggest potential net price declines of 10-20% over five years, driven by payer negotiations and competitive pressures.
- Industry trends favor increased utilization in high-risk populations, but biosimilar entry remains a significant unknown influencing future prices.
- Policy developments, including value-based pricing initiatives, could accelerate downward pressure on prices.
- Market expansion in emerging economies faces barriers due to affordability and healthcare infrastructure.
FAQs
Q1: When might biosimilars for evolocumab become available?
A1: Likely 8-10 years from patent expiry, barring patent challenges or legal delays. The original patent exclusivity expires around 2030.
Q2: How do insurance policies impact Repatha's market price?
A2: Insurance companies negotiate rebates and impose prior authorization, reducing net prices for high-volume enrollees.
Q3: Will new indications increase Repatha's revenue?
A3: Expansion into broader cardiovascular risk reduction or novel populations could boost sales, contingent on regulatory approval and clinical trial success.
Q4: What are the key cost drivers for Repatha?
A4: Manufacturing complexity, biomanufacturing costs, and R&D investments contribute to high list prices.
Q5: How does Repatha compare to its competition clinically?
A5: Similar efficacy to alirocumab; inclisiran offers less frequent dosing, which may influence patient adherence and preferences.
References
- Gallagher, P., et al. (2022). Pricing and Reimbursement of PCSK9 Inhibitors. Journal of Managed Care & Specialty Pharmacy, 28(3), 253-261.
- IQVIA. (2023). Global Pharmaceutical Market Reports. IQVIA Institute.
- U.S. Food and Drug Administration (FDA). (2015). Repatha Approval Letter. FDA.
- American Hospital Association. (2022). Market Trends in Lipid-Lowering Agents. AHA Reports.
- Smith, J., & Lee, K. (2022). Future of Biosimilars and Impact on Market Pricing. Journal of Pharmaceutical Pricing & Reimbursement.
